Dr. Richards on Unanswered Questions in Treating Bladder Cancer

Kyle A. Richards, MD
Published: Tuesday, Nov 03, 2015



Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

There have not been major advancements in bladder cancer over the last few decades: survival has remained stagnant and there continues to be a lack of approved therapies. Therefore, there are several areas of improvement in the field of bladder cancer, Richards explains.

For the future, Richard envisions more targeted therapies being available for patients. There is promising data from the Cancer Genome Atlas, which shows that researchers can individualize each patient’s bladder cancer and tailor treatments to those patients.

SELECTED
LANGUAGE


Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

There have not been major advancements in bladder cancer over the last few decades: survival has remained stagnant and there continues to be a lack of approved therapies. Therefore, there are several areas of improvement in the field of bladder cancer, Richards explains.

For the future, Richard envisions more targeted therapies being available for patients. There is promising data from the Cancer Genome Atlas, which shows that researchers can individualize each patient’s bladder cancer and tailor treatments to those patients.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x